Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022

SELL
$4.1 - $8.38 $2,513 - $5,136
-613 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$6.05 - $8.65 $3,708 - $5,302
613 New
613 $5,000

Others Institutions Holding KZIA

About KAZIA THERAPEUTICS LTD


  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $87.5M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.